Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Ledermann

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventionsA Karam, J A Ledermann, J-W Kim, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancerD M Provencher, C J Gallagher, W R Parulekar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventionsA Karam, J A Ledermann, J-W Kim, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancerD M Provencher, C J Gallagher, W R Parulekar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerC K Lee, R J Simes, C Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.
Pageof 7